StockpollyBeta
Get App

Categories·Biotech·New Drug Development

Oncology Biopharmaceuticals

+0.19% today·177 stocks

Stocks

By market cap · 177 stocks

  1. 1RVMDRevolution MedicinesDeveloper of RAS(ON) oncology candidates$40.98B−0.40%
  2. 2ONCBeOne Medicines (ADR)Developer of BRUKINSA and TEVIMBRA oncology medicines$39.07B−0.75%
  3. 3BNTXBioNTech (ADR)Comirnaty developer with an oncology pipeline$24.62B−0.15%
  4. 4GMABGenmab (ADR)Builder of antibody medicines and bispecific platforms$21.30B−0.49%
  5. 5EXELExelixisBuilder of the cabozantinib oncology franchise$14.38B+0.47%
  6. 6IBRXImmunityBioMaker of ANKTIVA and cellular immunotherapies$8.85B+1.66%
  7. 7CGONCG OncologyCretostimogene developer and contract manufacturer$6.90B+2.08%
  8. 8ERASErascaDeveloper of pan-RAS and pan-KRAS cancer drugs$5.22B+1.53%
  9. 9IOVAIovance BiotherapeuticsCommercial TIL therapy for solid tumors$4.55B−0.29%
  10. 10RLAYRelay TherapeuticsProtein-motion medicines for cancer and genetic disease$3.99B+1.87%
  11. 11TLXTelix PharmaceuticalsProstate imaging products and cancer radiopharmaceutical platform$3.83B+6.81%
  12. 12IDYAIDEAYA BiosciencesBiomarker-selected cancer drug developer$3.69B+0.69%
  13. 13TNGXTango TherapeuticsDeveloper of MTAP-selective PRMT5 cancer drugs$3.64B+0.90%
  14. 14ELVNEnliven TherapeuticsDeveloper of ELVN-001 for chronic myeloid leukemia$3.49B−0.34%
  15. 15LEGNLegend Biotech (ADR)CARVYKTI commercializer and CAR-T developer$3.43B+1.35%
  16. 16RCUSArcus BiosciencesDeveloper of casdatifan and oral inflammation drugs$3.26B+2.02%
  17. 17NRIXNurix TherapeuticsTargeted protein degradation drug developer$2.64B+0.65%
  18. 18CLDXCelldex TherapeuticsMast-cell antibody developer for inflammatory diseases$2.52B−1.79%
  19. 19BCRXBioCryst PharmaceuticalsRare-disease therapies centered on hereditary angioedema$2.23B+0.11%
  20. 20SLSSELLAS Life Sciences GroupDeveloper of GPS and SLS009 oncology candidates$2.12B−0.35%
  21. 21NUVBNuvation BioOncology developer behind IBTROZI$2.11B−0.15%
  22. 22URGNUroGen PharmaRTGel uro-oncology drug developer$2.10B+1.22%
  23. 23ZYMEZymeworksDeveloper of antibody medicines and royalty assets$1.97B−0.26%
  24. 24XNCRXencorDesigner of Fc-engineered, bispecific antibody drug candidates$1.86B+0.55%
  25. 25NBTXNanobiotix (ADR)Developer of radiotherapy-activated nanoparticle candidates$1.75B−0.43%
  26. 26INBXInhibrx BiosciencesBiologic developer behind ozekibart and INBRX-106$1.64B+2.39%
  27. 27SNDXSyndax PharmaceuticalsTargeted therapies for leukemia and chronic GVHD$1.60B+1.33%
  28. 28TYRATyra BiosciencesOral FGFR drug developer for cancer and achondroplasia$1.53B+0.02%
  29. 29BCAXBicara TherapeuticsDeveloper of bifunctional cancer antibodies$1.45B+1.37%
  30. 30DRTSAlpha Tau MedicalDeveloper of localized Alpha DaRT cancer therapy$1.40B−1.77%
  31. 31AVBPArriVent BioPharmaDeveloper of EGFR and ADC cancer candidates$1.39B+1.31%
  32. 32CGEMCullinan TherapeuticsT-cell engager developer for autoimmune disease and cancer$1.31B+1.03%
  33. 33ORICORIC PharmaceuticalsClinical-stage developer of resistance-targeted cancer therapies$1.31B+1.15%
  34. 34VORVor BiopharmaDeveloper of licensed telitacicept for autoimmune disease$1.19B−0.32%
  35. 35IMTXImmaticsPRAME-focused T-cell therapy developer$1.17B+0.81%
  36. 36AKTSAktis OncologyMiniprotein radioconjugates for solid tumors$1.14B+0.37%
  37. 37REPLReplimune GroupHSV-1 oncolytic immunotherapy developer$1.08B+0.17%
  38. 38CRVSCorvus PharmaceuticalsSoquelitinib-centered clinical immunotherapy developer$1.04B+1.13%
  39. 39JANXJanux TherapeuticsEngineers tumor-activated bispecific antibodies for cancer$1.04B+1.14%
  40. 40KURAKuraKOMZIFTI-centered oncology drug developer$1.03B+0.99%
  41. 41FTHFaeth TherapeuticsPIKTOR cancer-therapy developer$858.2M+0.05%
  42. 42OLMAOlema PharmaceuticalsDeveloper of endocrine cancer therapies$841.2M−0.30%
  43. 43ANLAdlai Nortye (ADR)Developer of RAS and cancer immunotherapy candidates$826.5M+1.73%
  44. 44CADLCandel TherapeuticsDeveloper of off-the-shelf viral cancer immunotherapies$821.4M+2.27%
  45. 45BLSMBlossomHill TherapeuticsOral oncology programs for EGFR, CLK and KRAS$779.4M−0.52%
  46. 46VSTMVerastemRAS/MAPK oncology drug developer$702.1M+1.50%
  47. 47IMMXImmix BiopharmaDeveloper of NXC-201 CAR-T therapy$678.4M+0.40%
  48. 48AURAAura BiosciencesVirus-like conjugates for organ-preserving oncology$657.9M−0.16%
  49. 49MNPRMonopar TherapeuticsWilson disease and radiopharmaceutical developer$641.2M+0.51%
  50. 50CBIOCrescent BiopharmaClinical developer of solid-tumor antibody therapies$603.6M+0.62%